Fig. 6

a Pooled analysis showing incidence difference of immune-related adverse effects between overweight cancer patients and normal patients receiving immune checkpoint inhibitors treatment; b Pooled analysis showing incidence difference of immune-related adverse effects between obese cancer patients and normal patients receiving immune checkpoint inhibitors treatment